At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 27, 2026 at 07:30 ET
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of November 27, 2026. The FDA is not planning an advisory committee meeting, and the company is poised to launch upon approval. This is a major regulatory milestone for a first-in-class therapy addressing a significant unmet need in a rare, progressive muscular dystrophy.
- FDA accepted NDA for BBP-418 with Priority Review; PDUFA target action date November 27, 2026.
- FDA not currently planning an advisory committee meeting to discuss the application.
- BBP-418 met all primary and secondary endpoints in Phase 3 FORTIFY trial at 12-month interim analysis.
- If approved, BBP-418 would be the first and only approved therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access